ArticlePloS one2026
Multifaceted response of microglia in the cuprizone model of demyelination.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The cuprizone diet paradigm, which involves selective depletion of oligodendrocytes and subsequent myelin loss, provides an excellent model to study the neuroimmune response to demyelination and remyelination. Microglia, the resident immune cells of the central nervous system, mount a robust response to cuprizone administration. However, the specific triggers and temporal trajectory of microglia activation are not well-defined. Moreover, it is unclear the extent to which microglia respond to cuprizone directly rather than to cuprizone-induced demyelination. In this study, we characterized the temporal dynamics of microglial activation in the corpus callosum during the early and peak phases of demyelination and during early remyelination following cuprizone withdrawal. Microglia number and area showed a dramatic increase by 1 week (early phase) and persisted throughout 4 weeks (peak phase), with partial recovery during early remyelination. The early demyelination phase was marked by morphological remodeling of microglia and engulfment of degraded myelin. This timepoint correlated with increased expression of Mertk and Apoe, and a concurrent decrease in the proinflammatory response genes, Tnf and Ifnb1. These findings indicate that the early neuroimmune response to cuprizone-induced demyelination is marked by an augmented phagocytic response accompanied by downregulation in inflammatory signaling. In the retina, which is devoid of oligodendrocytes or myelin, microglia did not display morphological alterations and instead downregulated CD68 expression in response to cuprizone administration. Our novel findings reveal that in addition to the microglial response to cuprizone-induced demyelination, cuprizone exerts direct effects on microglia even in absence of in vivo demyelination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.